Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
This study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the ATU setting.
Melanoma
OTHER: Non-interventional
Overall survival (OS) at 1 year, Overall survival (OS) for adult patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the ATU (Temporary Authorization for Use) program, at 1 year|Distribution of demographic characteristics of patients with advanced melanoma treated with nivolumab monotherapy in the ATU program, Distribution of demographic characteristics of patients with advanced melanoma treated with nivolumab monotherapy in the ATU program using descriptive statistics, at baseline|Distribution of clinical characteristics in patients with advanced melanoma treated with nivolumab monotherapy, Clinical characteristics will be summarized using descriptive statistics., at baseline|Overall survival (OS) at 2 years, Overall survival (OS) for adult patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the ATU (Temporary Authorization for Use) program, at 2 years
Progression-free survival (PFS), (PFS) will be measured by the time since nivolumab initiation to either the first disease progression date or last known tumor assessment date, or death, 1 year and 2 years|Objective response rate (ORR), ORR is the proportion of patients with an objective response. Objective response is measured by the sum of partial responses plus complete responses as assessed by (RECIST 1.1) Response Evaluation Criteria In Solid Tumors, 1 year and 2 years|Progression-free survival (PFS) as assessed by RECIST 1.1, PFS measured by time since index date (initial treatment with nivolumab) to either the first disease progression date or last known tumor assessment date, or death due to any cause, whichever occurs first as assessed by RECIST 1.1, at 1 year|Distribution of treatment patterns, Details on Prior and Evolution of Current Treatment Patterns will be summarized using descriptive statistics., up to 2 years|Incidence of select Grade 3, 4, or 5 adverse events (AEs), Select AEs include pulmonary, endocrine, gastrointestinal, hepatic, renal, cutaneous, and infusion reactions, up to 2 years
This study will be conducted with the aim of estimating the effectiveness, safety, patterns of use of nivolumab, and characteristics of patients with unresectable or metastatic melanoma, treated with nivolumab monotherapy in the ATU setting.